OptiBiotix Health PLC Grant of Options (7869U)

TIDMOPTI

RNS Number : 7869U

OptiBiotix Health PLC

17 July 2018

OPTIBIOTIX HEALTH PLC (the "Company")

Grant of Options

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the Company's Remuneration Committee has proposed a grant of options under the Company's approved EMI Scheme ("the Scheme"), to certain directors and employees.

 
 Director         Number of options   Exercise price 
 Neil Davidson    385,000             73p 
                 ------------------  --------------- 
 Sofia Kolyda     165,000             73p 
                 ------------------  --------------- 
 Others           165,000             73p 
                 ------------------  --------------- 
 

Under the rules of the Scheme the participants have up to 30 days from the date of offer, 13 July 2018, to complete the requisite documentation after which the Options will automatically lapse. Once the documentation has been received by the Company and approved by the board the option grant will become effective ("the Effective Date"). The options may be exercised up to 10 years from the Effective Date.

The options have performance criteria attached to them which includes a doubling in the share price and significant revenue targets. Option holders can only purchase and/or sell shares once these conditions have been met. This ensures a continued focus on commercial revenues and shareholder value creation.

A further announcement will be made confirming the Effective Date.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

Stephen O'Hara, CEO of OptiBiotix, commented: "The ability to attract and retain key staff who deliver to performance targets which build shareholder value is important to OptiBiotix' continued success. The granting of share options helps OptiBiotix compete with the remuneration packages offered by larger corporates and incentivises the team to focus both effort and activity on rapidly growing revenues and building shareholder value. These options are offered to staff do not become exercisable (i.e. sellable) until they achieve significant performance targets which if achieved will create substantive shareholder value".

For further information, please contact:

 
 OptiBiotix Health plc                                                www.optibiotix.com 
 Stephen O'Hara, Chief Executive                              Contact via Walbrook below 
 
 Cairn Financial Advisers LLP                                         Tel: [phone] 
 Liam Murray / Jo Turner 
 
 finnCap (Broker)                                                     Tel: [phone] 
 Adrian Hargrave / Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Abigail Wayne (Corporate Broking) 
 
 Walbrook PR Ltd                         Tel: [phone] or [e-mail] 
 Anna Dunphy                                                          Mob: [phone] 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHSFAFLMFASEFW

(END) Dow Jones Newswires

July 17, 2018 02:00 ET (06:00 GMT)